LOTTE BIOLOGICS and Ottimo Pharma sign antibody manufacturing contract

Simcere Zaiming reports first patient dosed in SIM0500 US Phase 1 trial in patients with relapsed/refractory multiple myeloma

IMUNON unveils promising Phase 2 translational data for IMNN-001 in advanced ovarian cancer

MAIA Biotechnology signs master clinical supply agreement with Roche to advance combination cancer therapies

Oncoinvent reports positive Phase 1/2a data for Radspherin in colorectal cancer patients with peritoneal metastases

TME Pharma and SERI partner to advance NOX-E36 in ophthalmology through option framework agreement

Incanthera reports breakthrough UV protection findings for Skin + CELL

Orion extends collaboration with Glykos to develop additional next-generation ADCs

Teva and Fosun Pharma partner to develop anti-PD1-IL2 therapy (TEV-56278) in immuno-oncology

EDX Medical and Spire Healthcare sign strategic diagnostic partnership agreement

Alligator Bioscience gains FDA support for Phase 3 mitazalimab dose in pancreatic cancer

Specialised Therapeutics and Incyte include two additional therapies in expanded partnership

Hoth Therapeutics looks to expand access for HT-001 to provide relief for cancer patients with severe skin toxicities

BioInvent reports positive Phase 1 results for BI-1206 and plans Phase 2a study in NSCLC and uveal melanoma

Curadev expands collaboration with Memorial Sloan Kettering Cancer Center for CRD3874-SI